66 patents
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
9 Jan 24
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after restimulation.
Ian Frank, Michael T. Lotze
Filed: 15 Aug 22
Utility
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
9 Jan 24
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
2 Jan 24
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Aug 22
Utility
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
21 Nov 23
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Jun 18
Utility
Processes for generating TIL products enriched for tumor antigen-specific T-cells
1 Aug 23
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 4 May 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
16 May 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
18 Apr 23
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 6 Jan 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
3 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
20 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
6 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 1 Jul 22
Utility
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
6 Sep 22
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Dec 18
Utility
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
2 Aug 22
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Filed: 17 Nov 17
Utility
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
12 Jul 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 28 Jul 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
21 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Dec 21
Utility
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
14 Jun 22
Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Krit Ritthipichai, Michael T. Lotze
Filed: 5 Jan 18
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 9 Dec 21
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
31 May 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
31 May 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21